Camber Pharmaceuticals Launches Generic Lunesta®
Eszopiclone Tablets, USP are indicated for the treatment of insomnia.
Camber Pharmaceuticals is pleased to announce the addition of Eszopiclone Tablets, USP to its product line. Between 50 and 70 million Americans suffer from chronic sleep disorders. Sleep deprivation can result in physical and mental health issues, increased risk of injury, reduced productivity, and even a higher chance of mortality.
Eszopiclone Tablets, USP are indicated for the treatment of insomnia. They have been shown to decrease sleep latency and improve sleep maintenance.
Eszopiclone Tablets, USP, are available in 1, 2, and 3 mg strengths in 30 and 100 count bottles.
To learn more about Eszopiclone Tablets, USP, please visit
Newsletter
Stay informed on drug updates, treatment guidelines, and pharmacy practice trends—subscribe to Pharmacy Times for weekly clinical insights.
Related Articles
- Camber Launches Colchicine Capsules
August 4th 2025
- Camber Launches Prucalopride Tablets
July 30th 2025